Investment Thesis: The stock has dropped by 78% over 5 years (from ~$180 in late 2021 to ~$39.09), destroying substantial shareholder value. At 21.6x Blended Forward P/E, Nike appears historically cheap relative to its 5-year average (~29.2x), yet it remains substantially expensive against every peer on EV/EBITDA (14.8x NTM vs. adidas at 7.6x, On Holding at 9.4x, and Deckers at 8.1x). The stock is currently priced for a margin recovery that even the Street only half believes in.

The one genuine near-term catalyst is the Investor Day on 16–17 November 2026, where CEO Elliott Hill must lay out a credible FY27–30 turnaround plan (JPM targets a 10.6% operating margin in FY30 with $2.68 EPS vs. Street consensus of $2.82). If Hill puts a credible operational bridge on the table, the stock will re-rate on the plan rather than current trailing metrics. If he does not, there is no other scheduled catalyst of comparable weight.

Portfolio Allocation Verdict: NOT A BUY FOR NEW CAPITAL. If a client wants sector exposure with secular growth attached, adidas (ADS GR) at 7.6x EV/EBITDA (+8.5% sales growth) or On Holding (ONON) at 9.4x (+16.5% sales growth) offer far superior risk/reward. Deckers (DECK) represents the closest structural comparison, trading at 12.4x FY1 earnings against Nike's 25.9x with a 30.2% EBIT margin. For existing long-term holders, holding through the November Investor Day is defensible. Buying more before then is not.

Metric	Target (12-Month)	Return Potential %	Target (3-Year)	Return Potential %
Price Target (Base)	$45.00	+15.1%	$58.00	+48.4%
EPS Projected	$1.75	-	$2.60	-
Implied FCF Yield	4.2%	-	5.8%	-

---

Nike, Inc. (NKE) is the world’s largest seller of athletic footwear, apparel, and equipment. The Nike Brand accounts for ~97.5% of total revenues ($46.4B in FY26), while Converse represents the remaining 2.5%.

Geographic Exposure & Current Trajectory (FY26 $46.4B):

1. North America (45%): $20.9B revenue. Showing early signs of bottoming (+3% currency-neutral in Q4 FY26) as wholesale relationships are restored.
2. EMEA (28%): $13.0B revenue. Down 6% CN in Q4 FY26 due to consumer softness and inventory rationalization.
3. Greater China (13%): $6.0B revenue. Facing structural contraction (-17% CN in Q4 FY26, -11% full-year) driven by aggressive domestic brand competition (Anta, Li-Ning) and localized retail traffic weakness.
4. APLA (14%): $6.5B revenue. Flat currency-neutral.

Distribution Channel Mix:

• Wholesale (58%): Re-embraced core channel under CEO Elliott Hill to re-establish retail shelf space across Foot Locker, JD Sports, and independent sporting goods stores.
• Nike Direct / DTC (42%): Owned retail stores and digital platforms (Nike.com, SNKRS).

---

Nike looks cheap against its own history, but is remarkably expensive against peers on growth-adjusted and operating metrics:

Footwear & Apparel Peer Comparison (Bloomberg Consensus / 18 August 2026)

Prices and EPS in local currency; Market Cap in USD (EUR/USD = 1.1585). Growth rates on respective fiscal years.

Metric	Nike (NKE)	adidas (ADS GR)	Lululemon (LULU)	Deckers (DECK)	On Holding (ONON)	Puma (PUM GR)
Price	$39.67	€153.70	$120.18	$91.57	$31.25	€25.69
Market Cap (USD)	$58.8B	$32.1B	$13.7B	$12.5B	$10.4B	$4.4B
Fiscal Year End	May	Dec	Jan	Mar	Dec	Dec
FY1 / FY2	May 27 / May 28	Dec 26 / Dec 27	Jan 27 / Jan 28	Mar 27 / Mar 28	Dec 26 / Dec 27	Dec 26 / Dec 27
P/E FY1	25.9x	16.4x	11.0x	12.4x	18.2x	nm
P/E FY2	20.4x	13.2x	10.7x	11.2x	15.4x	82.9x
EV/EBITDA NTM	14.8x	7.6x	5.5x	8.1x	9.4x	10.6x
EV/EBITDA FY2	13.0x	7.1x	5.5x	7.6x	8.7x	8.8x
Sales Growth FY1	-1.7%	+8.5%	-0.6%	+7.6%	+16.5%	-4.7%
Sales Growth FY2	+3.5%	+7.3%	+2.9%	+7.4%	+18.5%	+6.2%
EBIT Margin FY1	8.4%	9.0%	15.9%	30.2%	13.7%	-0.9%
EBIT Margin FY2	9.6%	9.9%	15.3%	30.3%	14.5%	3.0%
Dividend Yield (FY1E)	4.2%	2.3%	-	-	-	0.1%

Key Takeaway: Nike trades at a +95% premium on EV/EBITDA NTM vs. adidas (14.8x vs. 7.6x) and a +57% premium vs. On Holding (14.8x vs. 9.4x), despite delivering negative revenue growth (-1.7%) and an inferior operating margin (8.4% vs. 13.7% for ONON, 30.2% for DECK).

---

• The Core Moat: Nike still commands the world's most recognized athletic brand, unmatched athlete rosters (Mbappé, Haaland, Ronaldo, LeBron), and deep R&D capabilities (ZoomX, Air).
• The Execution Trap: Under prior leadership, over-distribution of heritage lifestyle sneakers (Air Force 1, Dunk, Jordan) destroyed pricing power and flooded secondary markets. Re-pivoting to wholesale takes time, carries lower gross margins than direct DTC, and requires clearing stale inventory at discounted rates.
• Running Franchise Traction: Nike Running has achieved 5 consecutive quarters of double-digit growth (+5 percentage points of market share gain), proving that the technical sport focus works. However, Running alone cannot immediately offset broader declines in casual lifestyle and China.

---

• FY26 Actuals: Revenue $46.4B (flat reported, -2% CN). Diluted GAAP EPS of $2.10 benefited from a $0.52/share one-off IEEPA tariff recovery ($986M pre-tax) following the Supreme Court ruling. Stripping out this item, underlying FY26 EPS was ~$1.58 (normalized Q4 EPS ~$0.20).
• Balance Sheet Fortress: Low debt (0.4x Net Debt/EBITDA, 2.19x current ratio) and steady cash flows allow Nike to support its $1.64/share dividend (4.2% yield).
• The CFRA vs. Consensus Disconnect:
  • CFRA Model: Projects FY27E EPS of $2.50 (+58% YoY) and FY28E EPS of $3.00, targeting $62.00.
  • Street Consensus (Bloomberg): Models FY27E EPS of $1.71 (23.8x P/E) and FY28E EPS of $2.30 (17.7x P/E).
  • Assessment: The CFRA forecast is excessively optimistic in the near term. A sudden margin rebound to >10% in FY27 is unrealistic given ongoing China contraction and wholesale channel mix dilution.

---

Consensus is mostly Hold, characterized by extreme analytical dispersion:

• Consensus Rating: 3.57 / 5.0 (Hold) B
  • Buys: 17 (38.6%)
  • Holds: 23 (52.3%)
  • Sells: 4 (9.1%)
• 12M Consensus Target Price: $50.65 (+29.6% return potential vs. spot $39.09) B
• Target Price Dispersion (3-Fold Spread):
  • High Target: $94.00 (Morningstar) / $75.00 (Jefferies) / $70.00 (Baird)
  • Low Target: $23.00 (BNP Paribas, Underperform) / $36.00 (Zacks) / $37.00 (Rothschild & Co Redburn)
  • Analysis: There is no true consensus; the $50.65 figure is simply an arithmetic midpoint between analysts who view Nike as a broken business facing secular share loss and those who anticipate a rapid doubling via mean-reverting margins.
• Recent Analyst Rating Actions (July–August 2026):
  • Hedgeye (Brian McGough): Reiterated Short (2026-08-17) B
  • Zacks: Underperform, PT $36.00 (2026-08-11) B
  • Bernstein (Aneesha Sherman): Outperform, PT $68.00 (2026-08-10) B
  • Guggenheim (Simeon Siegel): Buy, PT $60.00 (2026-08-10) B
  • BNP Paribas (Laurent Vasilescu): Underperform, PT $23.00 (2026-08-07) B
  • JPMorgan (Matthew R. Boss): Downgraded to Underweight, PT $40.00 (2026-08-04) B

---

The Core Catalyst

• Investor Day (16–17 November 2026): Elliott Hill must present a concrete bridge to double-digit operating margins (JPM models 10.6% by FY30 with $2.68 EPS). A credible plan re-rates the stock on forward multiple expansion; a vague presentation leaves the stock vulnerable to further downgrades.
  • Note that this event has already slipped once: it was originally planned for September and moved to November alongside the CFO transition (David Denton, ex-Pfizer, took over from Matthew Friend on 17 August 2026, announced 23 June 2026). A new CFO presenting a FY27–30 margin roadmap nine weeks into the job is a source of execution risk on the presentation itself, independent of the underlying plan.

Key Risks

• China Structural Erosion (Severity: High): Loss of share to Anta/Li-Ning (-17% CN Q4) showing no immediate inflection.
• Valuation Premium Vulnerability (Severity: High): Trading at 14.8x EV/EBITDA NTM with declining revenue leaves zero margin of safety if wholesale re-acceleration stalls.
• Promotional Clearance in EMEA (Severity: Medium): Gross margin drag while clearing classic inventory.

---

🐂 BULL CASE (Probability: 20%)

• Price Target (12-Month / 3-Year): $62.00 (+58.6%) / $80.00 (+104.7%)
• Implied EPS (12-Month / 3-Year): $2.30 / $3.20
• Implied Multiple: 27.0x P/E on FY27E EPS
• The Thesis: Elliott Hill delivers an outstanding Investor Day roadmap. Wholesale orders accelerate for Spring/Summer 2027, Running innovation spreads across mainstream footwear, and China stabilizes.

😐 BASE CASE (Probability: 55%)

• Price Target (12-Month / 3-Year): $45.00 (+15.1%) / $58.00 (+48.4%)
• Implied EPS (12-Month / 3-Year): $1.75 (near Street consensus $1.71) / $2.60
• Implied Multiple: 25.7x P/E on FY27E EPS / 22.3x P/E on FY28E
• The Thesis: Measured turnaround. Wholesale distribution improves, but margin recovery is delayed by channel mix and promotional discounting. Greater China remains a drag (-5% to flat). Stock trades in a range toward the $45–$50 zone.

🐻 BEAR CASE (Probability: 25%)

• Price Target (12-Month / 3-Year): $28.00 (-28.4%) / $35.00 (-10.5%)
• Implied EPS (12-Month / 3-Year): $1.35 / $1.80
• Implied Multiple: 20.7x P/E on depressed EPS (converging toward peer EV/EBITDA multiples)
• The Thesis: Investor Day fails to convince. Wholesale partners demand higher promotional allowances, On/Hoka continue taking running share, and China sales deteriorate further (-15% YoY).

---